New combo therapy for tough lung cancer tested in early trial
NCT ID NCT05403723
First seen Feb 22, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This early-stage trial is testing the safety of combining adaptive radiation with immunotherapy (durvalumab) and standard chemotherapy for people with extensive-stage small cell lung cancer that has stopped responding to platinum chemotherapy. The study aims to see how many patients experience side effects and whether the tumors shrink. It is currently on hold and not enrolling new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.